• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Five Prime Therapeutics, Inc. - Product Pipeline Review - 2012 Product Image

Five Prime Therapeutics, Inc. - Product Pipeline Review - 2012

  • Published: June 2012
  • Region: Global
  • 70 pages
  • Global Markets Direct

Five Prime Therapeutics, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Five Prime Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Five Prime Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Five Prime Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Five Prime Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Five Prime Therapeutics, Inc. - Brief Five Prime Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Five Prime Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- READ MORE >



List of Tables
List of Figures
Five Prime Therapeutics, Inc. Snapshot
Five Prime Therapeutics, Inc. Overview
Key Information
Key Facts
Five Prime Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Five Prime Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Five Prime Therapeutics, Inc. – Pipeline Products Glance
Five Prime Therapeutics, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Five Prime Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Five Prime Therapeutics, Inc. – Drug Profiles
Drug For Diabetes
Product Description
Mechanism of Action
R&D Progress
Drug For Immunology
Product Description
Mechanism of Action
R&D Progress
Drug For Oncology
Product Description
Mechanism of Action
R&D Progress
Drug For Respiratory Disease
Product Description
Mechanism of Action
R&D Progress
FP-1039
Product Description
Mechanism of Action
R&D Progress
FP-1069
Product Description
Mechanism of Action
R&D Progress
FPA 144
Product Description
Mechanism of Action
R&D Progress
FPA008
Product Description
Mechanism of Action
R&D Progress
FPT-025
Product Description
Mechanism of Action
R&D Progress
FPT-038
Product Description
Mechanism of Action
R&D Progress
FPT091
Product Description
Mechanism of Action
R&D Progress
Immunology Program
Product Description
Mechanism of Action
R&D Progress
Oncology Program
Product Description
Mechanism of Action
R&D Progress
Five Prime Therapeutics, Inc. – Pipeline Analysis
Five Prime Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Five Prime Therapeutics, Inc. – Pipeline Products By Target
Five Prime Therapeutics, Inc. – Pipeline Products by Route of Administration
Five Prime Therapeutics, Inc. – Pipeline Products By Mechanism of Action
Five Prime Therapeutics, Inc. – Recent Pipeline Updates
Five Prime Therapeutics, Inc. - Dormant Projects
Five Prime Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Five Prime Therapeutics, Inc., Deals Summary
Five Prime Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Five Prime Therapeutics Raises $10 Million In Venture Financing
Five Prime Therapeutics Secures $7.5 Million In Venture Financing
FivePrime Therapeutics Raises $40.28 Million In Venture Financing
Five Prime Therapeutics Secures Venture Financing
FivePrime Therapeutics Raises $11 Million In Venture Financing
Five Prime Therapeutics Raises $45 Million In Private Financing
Partnerships
Five Prime Therapeutics Enters Into Co-Development Agreement With GlaxoSmithKline
GlaxoSmithKline Expands Co-Development Agreement With Five Prime Therapeutics
Dyax Enters Into Research Agreement With Five Prime Therapeutics
Five Prime Therapeutics Enters Into Drug Discovery Agreement With GlaxoSmithKline
Five Prime Therapeutics Enters Into Co-Development Agreement With Fast Forward
Pfizer Enters Into An Agreement With FivePrime
FivePrime Enters Into Co-Development Agreement With Centocor
FivePrime Therapeutics Enters Into Research Agreement With Boehringer Ingelheim
Licensing Agreements
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line
Human Genome Sciences Enters Into Licensing Agreement With FivePrime Therapeutics For FP-1039
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Five Prime Therapeutics, Inc., Key Information
Five Prime Therapeutics, Inc., Key Facts
Five Prime Therapeutics, Inc. – Pipeline by Indication, 2012
Five Prime Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Five Prime Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Five Prime Therapeutics, Inc. – Phase I, 2012
Five Prime Therapeutics, Inc. – Pre-Clinical, 2012
Five Prime Therapeutics, Inc. – Discovery, 2012
Five Prime Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Five Prime Therapeutics, Inc. - Pipeline By Target, 2012
Five Prime Therapeutics, Inc. – Pipeline By Route of Administration, 2012
Five Prime Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012
Five Prime Therapeutics, Inc. – Recent Pipeline Updates, 2012
Five Prime Therapeutics, Inc. - Dormant Developmental Projects,2012
Five Prime Therapeutics, Inc., Deals Summary
Five Prime Therapeutics Raises $10 Million In Venture Financing
Five Prime Therapeutics Secures $7.5 Million In Venture Financing
FivePrime Therapeutics Raises $40.28 Million In Venture Financing
Five Prime Therapeutics Secures Venture Financing
FivePrime Therapeutics Raises $11 Million In Venture Financing
Five Prime Therapeutics Raises $45 Million In Private Financing
Five Prime Therapeutics Enters Into Co-Development Agreement With GlaxoSmithKline
GlaxoSmithKline Expands Co-Development Agreement With Five Prime Therapeutics
Dyax Enters Into Research Agreement With Five Prime Therapeutics
Five Prime Therapeutics Enters Into Drug Discovery Agreement With GlaxoSmithKline
Five Prime Therapeutics Enters Into Co-Development Agreement With Fast Forward
Pfizer Enters Into An Agreement With FivePrime
FivePrime Enters Into Co-Development Agreement With Centocor
FivePrime Therapeutics Enters Into Research Agreement With Boehringer Ingelheim
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line
Human Genome Sciences Enters Into Licensing Agreement With FivePrime Therapeutics For FP-1039

List of Figures
Five Prime Therapeutics, Inc. – Pipeline by Indication, 2012
Five Prime Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Five Prime Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Five Prime Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Five Prime Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS